Navigation Links
Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
Date:5/5/2008

WOODCLIFF LAKE, N.J., May 5 /PRNewswire/ -- Eisai Corporation of North America today announces the immediate appointment of Cynthia Schwalm as President of Eisai Inc. In her new role, Ms. Schwalm will have full operating responsibility for leading Eisai Inc., the U.S. commercial operation of Eisai Co., Ltd.

Ms. Schwalm brings to Eisai Inc. a strong track record of building high-performing organizations that drive global growth and nearly 25 years of senior healthcare experience in the fields of pharmaceuticals, biotechnology and medical devices. She will report to Lonnel Coats, President & COO, Eisai Corporation of North America. Previously, Mr. Coats held dual responsibilities, also serving as President & COO of Eisai Inc.

"Ms. Schwalm is an exciting addition to our company. She will be instrumental in driving Eisai's integration of MGI PHARMA and strengthening our presence in the U.S. as a top-20 pharmaceutical company," said Mr. Coats. "Ms. Schwalm has an extensive background in oncology, neurology, critical care and gastroenterology, areas of therapeutic focus for Eisai. She will be invaluable to our future growth, as we continue to advance our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families."

Ms. Schwalm joins Eisai from Amgen, Inc., where over the course of her five-year tenure she rose to Vice President and General Manager of the U.S. Oncology Business Unit, a group with annual revenues exceeding $5 billion. In this role she led the 500-person business unit, oversaw all oncology strategy and served as a member of Amgen's Senior Management Team responsible for talent development in medical affairs, drug development, regulatory, and health economic functions.

Prior to Amgen, Inc., Ms. Schwalm grew her pharmaceutical career over an 18-year period within Johnson & Johnson (J&J), holding positions of increasing responsibility at various J&J companies. During this time, Ms. Schwalm gained experience in oncology commercialization and also developed sales and marketing expertise in critical care, neurology/analgesia and gastroenterology. In her last assignment at J&J, she spent several years in the United Kingdom as the Managing Director of Ortho Biotech UK & Ireland.

Ms. Schwalm holds a Bachelor of Science degree in nursing from the University of Delaware and a Master of Business Administration degree from the Wharton School, University of Pennsylvania.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, Inc., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery. For more information about Eisai, please visit http://www.eisai.com.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
2. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
3. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
4. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
5. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
6. BioElectronics Corporation Receives Major Orders From Italian Distributor
7. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
8. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
9. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
10. Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date
11. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):